Potential of microRNA expression profile in predicting renal impairment risk in multiple myeloma patients

microRNA 表达谱预测多发性骨髓瘤患者肾功能损害风险的潜力

阅读:6
作者:Daijin Ren #, Yuwen Cai #, Gaosi Xu

Background

This study aimed to investigate the correlation of microRNA (miRNA) expression profile with renal impairment (RI) risk in multiple myeloma (MM) patients.

Conclusions

MiRNA expression profile is closely implicated in the RI development, and miR-103a-3p, miR-449c-5p, miR-877-5p, miR-455-3p and let-7a-5p may serve as novel biomarkers for RI risk in MM patients.

Methods

Plasma cell samples were isolated from bone marrows of 20 RI-MM patients and 20 non-RI-MM patients, and then proposed to microarray assay. Then 5 candidate miRNAs were selected and further validated by reverse transcription-quantitative polymerase chain reaction (RT-qPCR) in plasma cell samples from bone marrows of 60 RI-MM patients and 60 non-RI-MM patients.

Results

Principal component analysis and heatmap analysis revealed that miRNA expression profile could clearly distinguish RI-MM patients from non-RI-MM patients, further Valcano plots identified 28 upregulated and 13 downregulated miRNAs in RI-MM patients compared to non-RI-MM patients, and enrichment analysis observed that these dysregulated miRNAs were enriched in renal/inflammatory/apoptosis pathways and renal/inflammatory diseases. Subsequent RT-qPCR validation discovered that miR-103a-3p, miR-449c-5p and let-7a-5p were greatly increased, while miR-877-5p and miR-455-3p were dramatically decreased in RI-MM patients compared to non-RI-MM patients, and all of them could predict RI risk in MM patients by receiver operating characteristic (ROC) curve analysis. Most importantly, the combination of these five miRNAs presented with a great predictive value for RI risk in MM patients with an area under the curve (AUC) of 0.934, 95% CI: 0.895-0.974. Conclusions: MiRNA expression profile is closely implicated in the RI development, and miR-103a-3p, miR-449c-5p, miR-877-5p, miR-455-3p and let-7a-5p may serve as novel biomarkers for RI risk in MM patients.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。